

## References

### I-265

1. Budde LE, Assouline S, Shen LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase 1 dose-escalation study. *J Clin Oncol*. 2021; 40:481-491.
2. Lunsumio™ (mosunetuzumab-axgb), injection for intravenous use [package insert]. Genetech, Inc. San Francisco, CA. Revised 12/2022.
3. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Mosunetuzumab-axgb.
4. Micromedex DrugDex Compendium®. 2023. Mosunetuzumab-axgb.